JPMorgan raised the firm’s price target on Imax (IMAX) to $31 from $28 and keeps a Neutral rating on the shares as part of a Q3 earnings preview for the cinema group. The firm reduced its Q3 and 2025 box office outlook but has increased conviction in 2026 estimates after taking an early look at the first half release slate.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAX:
- IMAX: Strong Buy Rating Backed by Exceptional Performance and Growth Prospects
- IMAX’s Strong Market Position and Growth Potential Drive Buy Rating
- Taylor Swift plans return to movie theaters, Hollywood Reporter says
- Imax price target raised to $37 from $32 at Barrington
- Imax sets new record for local language box office